Pharmacological treatment of depression in people with a primary brain tumour

Beevers, Zachary C R; Hussain, Syed Fayyaz; Boele, Florien; Rooney, Alasdair G

doi:10.1002/14651858.cd006932.pub4

Cited by 19 publications

(12 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of evidence concerning the efficacy and tolerability of antidepressants ( 25 ) and antipsychotic treatments, the possible drug-to-drug interaction with CT ( 26 ), and the unknown benefits of cognitive-behavioral treatment (CBT) make the management of psychiatric symptoms in patients with brain tumors challenging. In this context, therapies associated with increased risk for suicide or suicide attempt, depression, or panic disorder should be avoided.…”

Section: Discussionmentioning

confidence: 99%

Levetiracetam Prophylaxis Therapy for Brain Tumor-Related Epilepsy (BTRE) Is Associated With a Higher Psychiatric Burden

et al. 2022

View full text Add to dashboard Cite

Purpose: Brain tumor-related epilepsy (BTRE) is a condition characterized by the development of seizures in the context of an undergoing oncological background. Levetiracetam (LEV) is a third-generation anti-seizure medication (ASM) widely used in BTRE prophylaxis. The study evaluated LEV neuropsychiatric side effects (SEs) in BTRE prophylaxis.Method: Twenty-eight patients with brain tumors were retrospectively selected and divided into two groups. In one group, we evaluated patients with a BTRE diagnosis using LEV (BTRE-group). The other group included patients with brain tumors who never had epilepsy and used a prophylactic ASM regimen with LEV (PROPHYLAXIS-group). Neuropsychiatric SEs of LEV were monitored using the Neuropsychiatric Inventory Questionnaire (NPI-Q) at the baseline visit and the 6- and 12-month follow-up.Results: Eighteen patients of the BTRE-group and 10 patients of the PROPHYLAXIS-group were included. Compared to the BTRE-group, the PROPHYLAXIS-group showed a higher severity of neuropsychiatric symptoms. According to Linear Mixed Models (LMM), a multiplicative effect was observed for the interaction between group treatment and time. For the caregiver distress score (CDS), only a time-effect was observed.Conclusion: Prophylactic ASM with LEV is associated with an increased frequency of neuropsychiatric SE. Accurate epileptological evaluations in patients with brain tumors are mandatory to select who would benefit most from ASM.

show abstract

Section: Discussionmentioning

confidence: 99%

Levetiracetam Prophylaxis Therapy for Brain Tumor-Related Epilepsy (BTRE) Is Associated With a Higher Psychiatric Burden

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Similarly, a Cochrane Review investigating pharmacologic treatment of patients with primary brain cancer reported that no studies met the inclusion criteria ( Rooney and Grant, 2010 ). This was repeated by the same group in 2013 ( Rooney and Grant, 2013 ) and 2020 ( Beevers et al., 2020 ) without evidence of high-quality studies that included updated queries. Within this review, brain cancer patients made up 0.4% of evaluated patients ( Fig.…”

Section: Discussionmentioning

confidence: 99%

A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer

Rabin

Kim

Mozny

et al. 2022

Brain, Behavior, & Immunity - Health

View full text Add to dashboard Cite

“…Therefore, a worse OS of users of antidepressant drugs at the start of maintenance cycle 4 may not be a mechanistic group effect of antidepressant drugs, but may rather reflect the association of depression with patient survival. In general, there is very limited data evaluating the benefits of any pharmacological treatment of depression in patients with glioma 41 . Patients able to receive maintenance cycle 4 are a selected population with overall a more favorable outcome, that is, it may be possible to detect associations that are otherwise blunted by the aggressiveness of GB.…”

Section: Discussionmentioning

confidence: 99%

Association of antidepressant drug use with outcome of patients with glioblastoma

Seliger

Oppong

Lefranc

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Depressive symptoms are common among patients with glioblastoma, but patients are often not treated with antidepressants. There is only limited evidence on the association of antidepressant drug use with survival in glioblastoma. We performed a pooled analysis of patients treated within the CENTRIC, CORE, AVAglio and ACT‐IV trials to explore the relation of antidepressant drug use with progression‐free (PFS) and overall survival (OS) at baseline, at the start of maintenance therapy and at the start of maintenance cycle 4. We further assessed the association of antidepressant drugs with seizure, cognition, fatigue and a diagnosis of depression. Among more than 1700 patients, we found no significant association between the use of antidepressants at baseline or at the start of maintenance therapy and PFS or OS. However, we found OS, but not PFS, to be significantly worse in patients using antidepressants at the start of maintenance cycle 4. After adjustment for antiepileptic drug use and despite showing a trend for increased risk, seizures were not significantly associated with antidepressant drug use, nor was there a change in mini mental state examination (MMSE) scores or fatigue by antidepressant drug use at baseline. However, there was a significant positive association between antidepressant use at the start of maintenance treatment and fatigue during maintenance treatment. The association of antidepressant use at the start of maintenance cycle 4 with inferior OS of glioblastoma patients requires independent confirmation and further study. Further prospective trials should evaluate efficacy, side effects and associations with outcome of antidepressants in glioblastoma.

show abstract

Pharmacological treatment of depression in people with a primary brain tumour

Cited by 19 publications

References 73 publications

Levetiracetam Prophylaxis Therapy for Brain Tumor-Related Epilepsy (BTRE) Is Associated With a Higher Psychiatric Burden

Levetiracetam Prophylaxis Therapy for Brain Tumor-Related Epilepsy (BTRE) Is Associated With a Higher Psychiatric Burden

A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer

Association of antidepressant drug use with outcome of patients with glioblastoma

Contact Info

Product

Resources

About